Clinical utility of 18F-FDG PET/CT in low 18F-FDG-avidity breast cancer subtypes
Authors:
- Ie Ryung YooIYIe Ryung Yoo
- Joo Hyun OJOJoo Hyun O
- Hyoungwoo KimHKHyoungwoo Kim
- Sung Hun KimSKSung Hun Kim
- Bong Joo KangBKBong Joo Kang
- 1 January 2018
- journal article
- research article
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 39 (1) , 35-43
Abstract
The aim of this study was to evaluate the diagnostic performance of fluorine-18-fluorodeoxyglucose (18F-FDG) PET/CT in initial axillary lymph node (ALN) staging and tumor recurrence in breast cancer subtypes with low 18F-FDG avidity in comparison with breast ultrasonography (US) and/or MRI. A total of 491 PET/CT exams from 192 patients with biopsy-proven breast cancer subtypes with low 18F-FDG avidity were enrolled retrospectively. Nodal status on staging and locoregional recurrence or metastasis on surveillance was confirmed either by pathology or by further clinical follow-up. Comparison was made with recent US and/or MRI. A total of 142 scans were for staging and 349 scans were for surveillance. For the staging, 127 tumors had perceptible 18F-FDG uptake. For the detection of ALN metastasis, the sensitivity, specificity, and accuracy were calculated to be 51.5, 94.6, and 84.7% for 18F-FDG PET/CT, 42.4, 90.1, and 79.2% for US, and 51.5, 88.3, and 79.9% for MRI, respectively. PET/CT showed significantly higher specificity than MRI. In the surveillance, the total recurrence rate was 4.3%. There were no cases of recurrence of mucinous or tubular carcinoma. PET/CT showed comparable diagnostic performance for locoregional recurrence compared with US in invasive lobular carcinoma. Distant metastasis developed in five patients (one stage II, four stage III), and all of these were identified by PET/CT alone. PET/CT showed comparable diagnostic performance with US and/or MRI for ALN staging and detecting tumor recurrence even when the primary breast cancer has low 18F-FDG avidity. 18F-FDG PET/CT also detected unsuspected distant metastasis in 36.4% of stage III patients. Surveillance PET/CT should be considered in advanced-stage invasive lobular carcinoma for early detection of recurrence.Keywords
This publication has 26 references indexed in Scilit:
- Spectrum of the Breast Lesions With Increased 18F-FDG Uptake on PET/CTClinical Nuclear Medicine, 2016
- 18F-FDG PET/CT for Staging and Restaging of Breast CancerJournal of Nuclear Medicine, 2016
- 18F-FDG PET/CT in the early prediction of pathological response in aggressive subtypes of breast cancer: review of the literature and recommendations for use in clinical trialsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2016
- Associations between the standardized uptake value of 18F-FDG PET/CT and the prognostic factors of invasive lobular carcinoma: in comparison with invasive ductal carcinomaWorld Journal of Surgical Oncology, 2015
- Effectiveness of Breast MRI and18F-FDG PET/CT for the Preoperative Staging of Invasive Lobular Carcinoma versus Ductal CarcinomaJournal of Breast Cancer, 2015
- The Prognostic Value of 18F-FDG PET/CT for Early Recurrence in Operable Breast Cancer: Comparison with TNM StageNuclear Medicine and Molecular Imaging, 2013
- Tubular Carcinoma of the Breast: Clinicopathologic Features and Survival Outcome Compared with Ductal CarcinomaIn SituJournal of Breast Cancer, 2013
- Lobular and non-lobular breast cancers differ regarding axillary lymph node metastasis: a cross-sectional study on 4,292 consecutive patientsBreast Cancer Research and Treatment, 2011
- Mucinous breast carcinoma: a large contemporary seriesThe American Journal of Surgery, 2008
- A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinomaBreast Cancer Research and Treatment, 2007